Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Innovation Council · Running

Piezo4Spine Piezo-driven theramesh: A revolutionary multifaceted actuator to repair the injured spinal cord

Coordinator
Agencia Estatal Consejo Superior De Investigaciones Cientificas, Spain
Runs
1 January 2023 to 31 December 2026
Status
Running
EU funding
€3.5m
Total cost
€3.5m
Partners
7 organisations in 6 countries
Type
European Innovation Council
Grant agreement
101098597

What the project is doing

In the project's own words, from its summary on CORDIS.

Piezo4Spine aims to develop a novel multifactorial therapy for spinal cord injury (SCI) conceived as a disruptive platform enabling unprecedented multiscale actuation to drive functional neural repair by more accurately tackling SCI complexity. It originally relies on the pivotal role that mechanotransduction plays in the physiology and physiopathology of tissue and organ functions, never explored before for SCI. We will develop a 3D bioprinted mesh containing nanocarriers with therapeutic agents acting at two pivotal aspects of neural repair: mechanotransduction and inhibitory scarring using gene therapy strategies.

Bioactive nanocarriers will base on cutting-edge nanoparticles whose release will be electrically triggered on-demand via wireless powering. Such 3D-theramesh offers a novel and exceptionally robust biomaterial for delivering agents at the lesion, controlling time and dose. Current advances on SCI therapies focus on rehabilitation, cell transplantation, drugs, biomaterials, and/or electrical stimulation. Although leading to partial sensory/motor recovery, chronic functional deficits limit daily living activities and shorten live expectancy in SCI patients, as they fail to promote successful axon regeneration at the lesion and awake lost functions.

By a multidisciplinary consortium combining scientific, technological, clinical and industrial partners enriched by their interdisciplinarity, we envision to overcome limitations of current technologies by tackling multiple cellular targets involved in neural regeneration after SCI with a balanced combination of therapeutic interventions able to optimally promote functional recovery. These radical science-to-technology breakthroughs could enable, if successful, novel technologies and therapies for SCI and many other neural and non-neural pathologies in which some, but not necessarily all, of these targets are involved.

Gender dimension will be implemented by ensuring that findings apply to society as a whole.

Topics

Who is involved

OrganisationCityCountryRole
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainCoordinator
Acib GmbHGrazAustriaParticipant
Universite Catholique De LouvainLouvain La NeuveBelgiumParticipant
Black Drop Biodrucker GmbHAachenGermanyParticipant
Servicio De Salud De Castilla La ManchaToledoSpainParticipant
Fondazione Istituto Italiano Di TecnologiaGenovaItalyParticipant
Universidade De CoimbraCoimbraPortugalParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI